Esperion Therapeutics (NASDAQ:ESPR) Issues Earnings Results, Beats Expectations By $0.06 EPS

Esperion Therapeutics (NASDAQ:ESPR) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.06, FiscalAI reports. The firm had revenue of $168.45 million for the quarter, compared to analysts’ expectations of $165.12 million.

Here are the key takeaways from Esperion Therapeutics’ conference call:

• Esperion agreed to acquire Corstasis, giving it global rights to Enbumyst (an FDA‑approved intranasal diuretic) with the deal expected to close in Q2 2026 and immediate cross‑selling opportunities into its existing cardiology sales footprint.
• Commercial momentum continued: Q4 sales grew 38% in the U.S., retail prescription equivalents rose 34%, prescribers increased ~25%, and the company expects favorable positioning in imminent U.S. dyslipidemia guidelines plus recognition for hsCRP reduction benefits.
• Financials strengthened (record 2025 revenue, $167.9M cash, $55M debt repayment), but Q4 collaboration revenue included a one‑time $90M Otsuka payment and 2026 partnership/manufacturing transfers create moving parts that could alter partner revenue timing and mix.
• Pipeline progress includes nomination of ESP‑2001 for primary sclerosing cholangitis with IND‑enabling work underway (clinic by year‑end) and two triple‑combination programs targeted for clinical/regulatory completion toward 2027 commercialization (potential ~70% LDL reductions).

Esperion Therapeutics Trading Down 11.2%

Shares of NASDAQ ESPR opened at $2.70 on Wednesday. The firm has a fifty day simple moving average of $3.35 and a two-hundred day simple moving average of $3.14. Esperion Therapeutics has a 12 month low of $0.69 and a 12 month high of $4.18. The firm has a market capitalization of $645.46 million, a PE ratio of -5.40, a price-to-earnings-growth ratio of 0.62 and a beta of 1.11.

Esperion Therapeutics News Summary

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Company reported solid top-line results and full‑year growth: Q4 revenue $168.45M and FY25 total revenue up 21% YoY to $403.1M; U.S. net product revenue rose 38% YoY — underpins ongoing commercial momentum. GlobeNewswire: Earnings Release
• Positive Sentiment: Company announced an acquisition alongside the quarter; some outlets and early trading reacted positively (reports of an ~8% intraday pop after the combination of revenue beat + acquisition). This could add strategic scale or pipeline heft, depending on transaction details. MSN: Shares rise after revenue tops forecasts and acquisition
• Neutral Sentiment: Company hosted an earnings call and published the slide deck and transcripts — useful for investors who want management’s color on growth drivers, guidance, and upcoming catalysts. MarketBeat: Earnings / Call Materials Yahoo: Call Transcript
• Neutral Sentiment: Short-interest data published around the period showed anomalous “0 shares” values and 0.0 days‑to‑cover — likely a reporting/data artifact rather than a meaningful short squeeze signal. (Monitor official exchange short-interest releases for clarity.)
• Negative Sentiment: Some outlets flagged a miss versus a specific EPS estimate (Zacks: $0.22 reported vs $0.23 Zacks estimate) and framed the quarter as “mixed,” which pressured sentiment and helped trigger intraday selling in some trade windows. Zacks: Misses Q4 Estimates
• Negative Sentiment: Coverage noted a “mixed” Q4 and consequent share weakness despite retail interest; that narrative — mixed beat/miss headlines plus profit‑taking after an early run — likely contributed to the stock moving lower on the day. MSN: Stock falls after mixed Q4

Insider Buying and Selling at Esperion Therapeutics

In related news, CFO Benjamin Halladay sold 7,337 shares of the business’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total transaction of $26,926.79. Following the transaction, the chief financial officer owned 467,525 shares in the company, valued at $1,715,816.75. The trade was a 1.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders have sold 15,543 shares of company stock worth $55,709. Insiders own 1.70% of the company’s stock.

Institutional Trading of Esperion Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Raymond James Financial Inc. grew its holdings in shares of Esperion Therapeutics by 46.4% during the 3rd quarter. Raymond James Financial Inc. now owns 60,093 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 19,036 shares during the period. ExodusPoint Capital Management LP purchased a new position in shares of Esperion Therapeutics in the 4th quarter valued at approximately $129,000. State of Wyoming lifted its stake in shares of Esperion Therapeutics by 36.2% in the 2nd quarter. State of Wyoming now owns 122,532 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 32,596 shares during the period. Abel Hall LLC boosted its position in shares of Esperion Therapeutics by 138.4% during the fourth quarter. Abel Hall LLC now owns 28,943 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 16,801 shares in the last quarter. Finally, EntryPoint Capital LLC bought a new stake in shares of Esperion Therapeutics during the fourth quarter valued at approximately $87,000. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ESPR. HC Wainwright restated a “buy” rating on shares of Esperion Therapeutics in a research report on Tuesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Esperion Therapeutics in a research note on Wednesday, November 12th. Piper Sandler began coverage on Esperion Therapeutics in a report on Tuesday, November 25th. They set an “overweight” rating and a $9.00 price target on the stock. Citigroup reaffirmed a “market outperform” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. Finally, Wall Street Zen cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.25.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.